TY - JOUR
T1 - Microfluidic-assisted synthesis of multifunctional iodinated contrast agent polymeric nanoplatforms
AU - Chiesa, Enrica
AU - Greco, Antonietta
AU - Dorati, Rossella
AU - Conti, Bice
AU - Bruni, Giovanna
AU - Lamprou, Dimitrios
AU - Genta, Ida
PY - 2021/2/27
Y1 - 2021/2/27
N2 - Contrast Induced
Nephropathy is the most severe side-effect arising after non-ionic iodinated
contrast agents (CAs) intravenous administration. The use of antioxidants (i.e.,
N-Acetylcysteine; NAC) is one of the attempted prevention approaches. Herein,
we describe the microfluidic-assisted synthesis of iodinated polymeric
nanoparticles (NPs) as new multifunctional blood pool CA. The aim of this
research is to co-encapsulate Iohexol (IOX; iodinated CA) and NAC (preventive
agent) into poly-D,L-lactide-co-glycolide (PLGA) and PEGylated-PLGA (PLGA-PEG)
NPs to exploit CA diagnostic proprieties and NAC preventing antioxidant
activity. A microfluidic-assisted nanoprecipitation protocol has been set-up for
PLGA and PLGA-PEG NPs, evaluating the effect of formulation and microfluidic
parameters by analysing the size, PDI and IOX and NAC encapsulation efficiency.
The optimized NPs (PLGA-PEG, L:G 50:50, 5% PEG, Mw 90 kDa) formulated with a size of 67±2.8 nm with PDI<0.2, spherical
shape, and an IOX and NAC encapsulation efficiency of 38% and 20%,
respectively. The IOX and NAC encapsulation was confirmed by FTIR and DSC. In
vitro release study showed an IOX retention into the polymeric matrix and
NAC sustained release up to 24-48h stating microfluidics as
powerful tool for the formulation of multifunctional nanoplatforms. Finally, the protective effect of
NPs and NAC were preliminary assessed on human kidney cells.
AB - Contrast Induced
Nephropathy is the most severe side-effect arising after non-ionic iodinated
contrast agents (CAs) intravenous administration. The use of antioxidants (i.e.,
N-Acetylcysteine; NAC) is one of the attempted prevention approaches. Herein,
we describe the microfluidic-assisted synthesis of iodinated polymeric
nanoparticles (NPs) as new multifunctional blood pool CA. The aim of this
research is to co-encapsulate Iohexol (IOX; iodinated CA) and NAC (preventive
agent) into poly-D,L-lactide-co-glycolide (PLGA) and PEGylated-PLGA (PLGA-PEG)
NPs to exploit CA diagnostic proprieties and NAC preventing antioxidant
activity. A microfluidic-assisted nanoprecipitation protocol has been set-up for
PLGA and PLGA-PEG NPs, evaluating the effect of formulation and microfluidic
parameters by analysing the size, PDI and IOX and NAC encapsulation efficiency.
The optimized NPs (PLGA-PEG, L:G 50:50, 5% PEG, Mw 90 kDa) formulated with a size of 67±2.8 nm with PDI<0.2, spherical
shape, and an IOX and NAC encapsulation efficiency of 38% and 20%,
respectively. The IOX and NAC encapsulation was confirmed by FTIR and DSC. In
vitro release study showed an IOX retention into the polymeric matrix and
NAC sustained release up to 24-48h stating microfluidics as
powerful tool for the formulation of multifunctional nanoplatforms. Finally, the protective effect of
NPs and NAC were preliminary assessed on human kidney cells.
KW - contrast-induced nephropathy
KW - multifunctional contrast agent
KW - iohexol
KW - N-acetylcysteine
KW - Microfluidics
KW - PLGA
KW - Nanoparticles
M3 - Article
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
SN - 0378-5173
ER -